CLDN14-AS1: A Potential Drug Target and Biomarker (G105369301)

Target Name: CLDN14-AS1

NCBI ID: G105369301

CLDN14-AS1

Other Name(s): CLDN14 antisense RNA 1, transcript variant X3 | PTAR | LOC105369301 variant X5 | CLDN14 antisense RNA 1 | Uncharacterized LOC105369301, transcript variant X5

CLDN14-AS1: A Potential Drug Target and Biomarker

CLDN14-AS1 is a clusterin protein that is expressed in various tissues throughout the body. It is a member of the CLDN gene family, which encodes a family of tight junction proteins that help to maintain tissue barriers and prevent the infiltration of foreign particles. CLDN14-AS1 is unique among its family members because it is highly expressed in the placenta, which is a vital organ that plays a critical role in the development and maintenance of fetal tissues.

The placenta is also the site where many drugs are tested for their safety and effectiveness. Many drugs that are used to treat various diseases, such as cancer, have been shown to be effective in the placenta, suggesting that CLDN14-AS1 may be a useful drug target.

One of the reasons why CLDN14-AS1 is a promising drug target is because it is involved in several important cellular processes that are critical for fetal development and growth. For example, CLDN14-AS1 is involved in the formation of tight junctions, which are critical for the development of tissues that are properly barrier-controlled. It is also involved in the regulation of cell signaling pathways that are critical for the development of tissues that are properly shaped and organized.

In addition to its role in fetal development, CLDN14-AS1 is also involved in the regulation of adult tissue repair and regeneration. It is one of the proteins that is involved in the formation of the blood-brain barrier, which is a critical barrier that helps to protect the brain from foreign particles and other harmful substances. It is also involved in the regulation of the angiogenesis that is the process by which new blood vessels are formed in response to the need for oxygen and nutrients.

The potential benefits of targeting CLDN14-AS1 with a drug are numerous. Depending on the disease that is being treated, CLDN14-AS1 may be used to block the formation of new blood vessels, which can be effective in treating certain types of cancer. It may also be used to stimulate the growth and differentiation of certain types of cells, which can be effective in treating certain types of genetic disorders.

Another potential benefit of targeting CLDN14-AS1 with a drug is that it may be able to treat certain types of genetic disorders that are caused by the regulation of gene expression. For example, CLDN14-AS1 has been shown to be involved in the regulation of gene expression in various tissues, including the placenta. This suggests that it may be a useful target for treating certain types of genetic disorders that are caused by the regulation of gene expression.

In conclusion, CLDN14-AS1 is a unique protein that is involved in several important cellular processes that are critical for fetal development and growth. Its potential as a drug target makes it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the role of CLDN14-AS1 in the development and treatment of various diseases.

Protein Name: CLDN14 Antisense RNA 1

The "CLDN14-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN14-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets